Posttransplant Vorinostat therapy for the prevention of early relapse after allogeneic stem cell transplantation against mycosis fungoides/Sezary syndrome
Not Applicable
- Conditions
- mycosis fungoides/Sezary syndrome
- Registration Number
- JPRN-UMIN000010774
- Lead Sponsor
- orth Japan Hematology Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Diabetes uncontrollable (2)Uncontrollable hypertension. (3)Current active infection. (4)Hepatitis B virus antigen (HBsAg), Hepatitis C virus RNA, or HIV antibody- positive. (5)Current active cancer. (6)Pregnant or nursing women or women who may be pregnant. (7)Uncontrollable mental illness. (8)Other unsuitable reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method More than grade 4 (NCI-CTCAE version 4.0) of non-hematological toxicity within day 180 after allogeneic stem cell transplantation
- Secondary Outcome Measures
Name Time Method